Does Rallies show Form 4 insider transactions for ARWR?

Yes. Rallies tracks ARWR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ARWR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARWR. It does not provide personalized investment advice.

ARWR (Arrowhead Research Corporation) Stock Analysis - Insider Trades

Arrowhead Research Corporation (ARWR) is a publicly traded Healthcare sector company. As of May 20, 2026, ARWR trades at $77.11 with a market cap of $10.42B and a P/E ratio of -35.25. ARWR moved +5.35% today. Year to date, ARWR is +7.95%; over the trailing twelve months it is +364.93%. Its 52-week range spans $9.57 to $82.26. Analyst consensus is strong buy with an average price target of $89.25. Rallies surfaces ARWR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ARWR stock inside the company?

Recent ARWR insider activity includes Lu Hongbo sold 2.97K, Hamilton James C sold 10.00K, Apel Daniel Joseph sold 3.21K, Apel Daniel Joseph sold 1.16K, and Apel Daniel Joseph sold 8.73K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ARWR Key Metrics

Key financial metrics for ARWR
Metric	Value
Price	$77.11
Market Cap	$10.42B
P/E Ratio	-35.25
EPS	$-2.17
Dividend Yield	0.00%
52-Week High	$82.26
52-Week Low	$9.57
Volume	1.25M
Avg Volume	0
Revenue (TTM)	$622.01M
Net Income	$-271.86M
Gross Margin	0.00%

Recent ARWR Insider Trades

Lu Hongbo sold 2.97K (~$228.33K) on May 12, 2026.
Hamilton James C sold 10.00K (~$750.00K) on Apr 23, 2026.
Apel Daniel Joseph sold 3.21K (~$224.91K) on Apr 22, 2026.
Apel Daniel Joseph sold 1.16K (~$81.51K) on Apr 22, 2026.
Apel Daniel Joseph sold 8.73K (~$627.86K) on Apr 22, 2026.

Latest ARWR News

Arrowhead Shares Jump 6.95% on Surge in AI-Driven Cardiac Diagnostics Market Forecast — May 12, 2026
Arrowhead Projects $73.8M Q2 Revenue, Gains ARO-PNPLA3 License and Australian Approval — May 7, 2026
Arrowhead climbs as traders buy ahead of May 7 earnings and EU Redemplo momentum — May 6, 2026
Arrowhead Grants Madrigal Global Rights to ARO-PNPLA3 with $25M Upfront, $975M Milestones — May 6, 2026
Arrowhead (ARWR) slides ahead of May 7 earnings webcast as caution builds — May 5, 2026

ARWR Analyst Consensus

10 analysts cover ARWR: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.25.

Common questions about ARWR

Who is trading ARWR stock inside the company?: Recent ARWR insider activity includes Lu Hongbo sold 2.97K, Hamilton James C sold 10.00K, Apel Daniel Joseph sold 3.21K, Apel Daniel Joseph sold 1.16K, and Apel Daniel Joseph sold 8.73K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ARWR?: Yes. Rallies tracks ARWR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ARWR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARWR. It does not provide personalized investment advice.